Table of Contents
ISRN Endocrinology
Volume 2012 (2012), Article ID 375231, 9 pages
http://dx.doi.org/10.5402/2012/375231
Clinical Study

Correlation between Calcitonin Levels and [𝟏𝟖F]FDG-PET/CT in the Detection of Recurrence in Patients with Sporadic and Hereditary Medullary Thyroid Cancer

1Nuclear Medicine Department, Evangelismos General Hospital, Ipsilantou 45-47, 10676 Athens, Greece
2Department of Endocrinology, Evangelismos General Hospital, Ipsilantou 45-47, 10676 Athens, Greece
3Department of Endocrinology, Polikliniki General Hospital, Pireos 3, 10552 Athens, Greece
4Department of Radiology and CT Department, Evangelismos General Hospital, Ipsilantou 45-47, 10676 Athens, Greece
5Department of Endocrinology, Alexandra General Hospital, Vassilissis Sofias 80, 11528 Athens, Greece

Received 10 February 2012; Accepted 28 February 2012

Academic Editors: M. Krebs and S. La Rosa

Copyright © 2012 Evangelia Skoura et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Thyroid Association Guidelines Task Force, R. T. Kloos, C. Eng et al., “Medullary thyroid cancer: management guidelines of the American Thyroid Association,” Thyroid, vol. 19, no. 6, pp. 565–612, 2009. View at Google Scholar · View at Scopus
  2. M. Schott, H. S. Willenerg, C. Sagert et al., “Identification of occult metastases of medullary thyroid carcinoma by pentagastrin-stimulated intravenous calcitonin sampling followed by targeted surgery,” Clinical Endocrinology, vol. 66, pp. 405–409, 2007. View at Google Scholar
  3. D. J. Marsh, D. L. Learoyd, and B. G. Robinson, “Medullary thyroid carcinoma: recent advances and management update,” Thyroid, vol. 5, no. 5, pp. 407–424, 1995. View at Google Scholar · View at Scopus
  4. S. Leboulleux, E. Baudin, J. P. Travagli, and M. Schlumberger, “Medullary thyroid carcinoma,” Clinical Endocrinology, vol. 61, no. 3, pp. 299–310, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. W. H. Jang, J. Y. Choi, J. I. Lee et al., “Localization of medullary thyroid carcinoma after surgery using 11C-methionine pet/ct: comparison with 18F-FDG PET/CT,” Endocrine Journal, vol. 57, no. 12, pp. 1045–1054, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Schlumberger, F. Carlomagno, E. Baudin, J. M. Bidart, and M. Santoro, “New therapeutic approaches to treat medullary thyroid carcinoma,” Nature Clinical Practice Endocrinology and Metabolism, vol. 4, no. 1, pp. 22–32, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Fugazzola, A. Pinchera, F. Luchetti et al., “Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma,” International Journal of Biological Markers, vol. 9, no. 1, pp. 21–24, 1994. View at Google Scholar · View at Scopus
  8. M. Schlumberger and F. Pacini, “Medullary thyroid carcinoma,” in Thyroid Tumors, M. Schlumberger and F. Pacini, Eds., pp. 305–332, Editions Nucleon, Paris, France, 2nd edition, 2003. View at Google Scholar
  9. S. Franc, P. Niccoli-Sire, R. Cohen et al., “Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma,” Clinical Endocrinology, vol. 55, no. 3, pp. 403–409, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Modigliani, R. Cohen, J. M. Campos et al., “Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine,” Clinical Endocrinology, vol. 48, pp. 265–273, 1998. View at Google Scholar
  11. A. Machens, P. Niccoli-Sire, J. Hoegel et al., “Early malignant progression of hereditary medullary thyroid cancer,” The New England Journal of Medicine, vol. 349, no. 16, pp. 1517–1525, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Rubello, L. Rampin, C. Nanni et al., “The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study,” European Journal of Surgical Oncology, vol. 34, no. 5, pp. 581–586, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Clarke, “Medullary thyroid cancer,” in Nuclear Medicine in Clinical Diagnosis and Treatment, P. J. Ell and S. S. Gambhir, Eds., pp. 165–174, Churcill Livingstone, Philadelphia, Pa, USA, 3rd edition, 2004. View at Google Scholar
  14. A. Iagaru, R. Masamed, P. A. Singer, and P. Conti, “Detection of occult medullary thyroid cancer recurrence with 2-Deoxy-2-[F-18]fluoro-d-glucose-PET and PET/CT,” Molecular Imaging and Biology, vol. 9, no. 2, pp. 72–77, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. S. C. Ong, H. Schöder, S. G. Patel et al., “Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels,” Journal of Nuclear Medicine, vol. 48, no. 4, pp. 501–507, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Skoura, P. Rondogianni, M. Alevizaki et al., “Role of [18F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer,” Nuclear Medicine Communications, vol. 31, no. 6, pp. 567–575, 2010. View at Google Scholar · View at Scopus
  17. K. Brandt-Mainz, S. P. Müller, R. Görges, B. Saller, and A. Bockisch, “The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer,” European Journal of Nuclear Medicine, vol. 27, no. 5, pp. 490–496, 2000. View at Google Scholar · View at Scopus
  18. T. Gawlik, A. d’Amico, S. Szpak-Ulczok et al., “The prognostic value of tumor markers doubling times in medullary thyroid carcinoma—preliminary report,” Thyroid Research, vol. 3, article 10, 2010. View at Publisher · View at Google Scholar
  19. S. A. Wells Jr., S. B. Baylin, D. S. Gann et al., “Medullary thyroid carcinoma: relationship of method of diagnosis to pathologic staging,” Annals of Surgery, vol. 188, pp. 377–383, 1978. View at Google Scholar
  20. A. L. Giraudet, A. Al Ghulzan, A. Auperin et al., “Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times,” European Journal of Endocrinology, vol. 158, no. 2, pp. 239–246, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. A. L. Giraudet, D. Vanel, S. Leboulleux et al., “Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 11, pp. 4185–4190, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Hoegerle, C. Altehoefer, N. Ghanem, I. Brink, E. Moser, and E. Nitzsche, “18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels,” European Journal of Nuclear Medicine, vol. 28, no. 1, pp. 64–71, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Szakáll Jr., O. Esik, G. Bajzik et al., “18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma,” Journal of Nuclear Medicine, vol. 43, no. 1, pp. 66–71, 2002. View at Google Scholar · View at Scopus
  24. N. Khan, N. Oriuchi, T. Higuchi, and K. Endo, “Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas,” Cancer Control, vol. 12, no. 4, pp. 254–260, 2005. View at Google Scholar · View at Scopus
  25. M. Diehl, J. Risse, K. Brandt-Mainz et al., “Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study,” European Journal of Nuclear Medicine, vol. 28, no. 11, pp. 1671–1676, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. J. W. de Groot, T. P. Links, P. L. Jager, T. Kahraman, and J. T. Plukker, “Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer,” Annals of Surgical Oncology, vol. 11, no. 8, pp. 786–794, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Bockisch, K. Brandt-Mainz, R. Görges, S. Müller, J. Stattaus, and G. Antoch, “Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner,” Acta Medica Austriaca, vol. 30, no. 1, pp. 22–25, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. B. G. Conry, N. D. Papathanasiou, V. Prakash et al., “Comparison of 68Ga-DOTATATE and 18F- fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 1, pp. 49–57, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Oudoux, P. Y. Salaun, C. Bournaud et al., “Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 12, pp. 4590–4597, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Adams, R. Baum, T. Rink, P. M. Schumm-Dräger, K. H. Usadel, and G. Hor, “Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours,” European Journal of Nuclear Medicine, vol. 25, no. 1, pp. 79–83, 1998. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Marini, A. Falchetti, F. Del Monte et al., “Multiple endocrine neoplasia type 2,” Orphanet Journal of Rare Diseases, vol. 1, no. 1, article 45, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Pestourie, B. Thézé, B. Kuhnast et al., “PET imaging of medullary thyroid carcinoma in MEN2A transgenic mice using 6-[18F]F-L-DOPA,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 1, pp. 58–66, 2010. View at Publisher · View at Google Scholar · View at Scopus